Table 1.
Baseline characteristics of study population.
| Variable | EC n = 103 | PMB n = 113 | All n = 216 |
|---|---|---|---|
| n (%) | n (%) | n (%) | |
| Age at diagnosis | |||
| <60 years | 24 (23.3) | 79 (69.9) | 103 (47.7) |
| 60–70 years | 32 (31.1) | 18 (15.9) | 50 (23.1) |
| >70 years | 47 (45.6) | 16 (14.2) | 63 (29.2) |
| BMI at diagnosis | |||
| <25 kg/m2 | 15 (14.6) | 34 (30.1) | 49 (22.7) |
| 25–29.9 kg/m2 | 25 (24.3) | 29 (25.7) | 54 (25.0) |
| ≥30 kg/m2 | 63 (61.2) | 46 (40.7) | 109 (50.5) |
| Missing data | 4 (3.5) | 4 (1.9) | |
| Presenting complaint | |||
| PMB | 89 (86.4) | 113 (100) | 202 (93.5) |
| Abnormal bleeding – othera | 5 (4.9) | 5 (2.3) | |
| Otherb | 9 (8.7) | 9 (4.2) | |
| Diagnosis | |||
| Endometrial cancer | 100 (97.1) | 4 (3.5) | 104 (48.1) |
| Atypical hyperplasia | 1 (1.0) | 3 (2.7) | 3 (1.4) |
| Cervical cancer | 2 (1.9) | 1 (0.9) | 2 (0.9) |
| Ovarian cancer | 1 (0.9) | 1 (0.5) | |
| Fallopian tube cancer | 0 | 2 (0.9) | |
| Benign endometrial polyp | 31 (27.4) | 31 (14.4) | |
| Benign cervical polyp | 6 (5.3) | 6 (2.9) | |
| Vulvovaginal atrophy | 39 (34.5) | 39 (18.1) | |
| Unscheduled bleeding on HRT | 5 (4.4) | 5 (2.3) | |
| Other | 2 (1.8) | 2 (0.9) | |
| No cause for bleeding found | 21 (18.6) | 21 (9.7) | |
| EC Cases | |||
| Histological subtype | 58 (58.0) | 3 (75.0) | 61 (28.2) |
| Endometrioid | 42 (42.0) | 1 (25.0) | 43 (20.0) |
| Non-endometrioid | 12 (12.0) | 0 | 12 (5.6) |
| Serous | 7 (7.0) | 0 | 7 (2.8) |
| Clear cell | 15 (15.0) | 1 (25.0) | 16 (7.4) |
| Carcinosarcoma | 7 (7.0) | 0 | 7 (3.3) |
| Mixed Mucinous | 1 (1.0) | 0 | 1 (0.5) |
| EC Cases | |||
| Grade 1 | 36 (36.0) | 2 (50.0) | 38 (17.6) |
| 2 | 17 (17.0) | 1 (25.0) | 18 (8.4) |
| 3 | 47 (47.0) | 1 (25.0) | 48 (22.2) |
| EC Cases | |||
| FIGO (2009) Stage 1 | 65 (65.0) | 3 (75.0) | 68 (31.5) |
| 2 | 13 (13.0) | 0 | 13 (6.0) |
| 3 | 18 (18.0) | 1 (25.0) | 19 (8.8) |
| 4 | 4 (4.0) | 0 | 4 (1.9) |
| Lymphovascular space invasion | |||
| Absent | 58 (58.0) | 2 (50.0) | 60 (27.8) |
| Present | 35 (35.0) | 2 (50.0) | 37 (17.1) |
| Missing datac | 7 (7.0) | 7 (3.2) | |
| Depth of myometrial invasion | |||
| <50% | 53 (53.00) | 2 (50.0) | 55 (25.5) |
| ≥50% | 41 (41.00) | 2 (50.0) | 43 (19.9) |
| Missing datac | 6 (6.0) | 6 (2.8) | |
EC endometrial cancer, PMB postmenopausal bleeding, BMI body mass index, HRT hormone replacement therapy.
aAbnormal pre- or peri-menopausal bleeding.
bHaematuria, haematocolpos, pelvic mass, abdominal bloating or pain, subfertility.
cIncluding five women who did not have surgery, e.g. for advanced disease, fertility-sparing or medical fitness reasons.